backgroud
influenza
viru
still
huge
threat
worldwid
public
health
host
dehydrogenas
impdh
involv
synthesi
guanin
nucleotid
known
potenti
target
inhibit
replic
virus
herein
evalu
antivir
activ
benzoheterocycl
amin
deriv
design
inhibit
impdh
result
result
demonstr
inhibit
replic
influenza
b
virus
includ
oseltamivir
amantadin
resist
strain
vitro
mechanist
neuraminidas
inhibit
assay
hemagglutin
inhibit
assay
suggest
directli
target
two
envelop
glycoprotein
requir
viral
adsorpt
releas
instead
compound
could
depress
activ
impdh
type
ii
base
find
confirm
provid
strong
inhibit
replic
respiratori
syncyti
viru
coronaviru
enteroviru
divers
strain
coxsacki
b
viru
conclus
identifi
small
molecul
inhibitor
impdh
might
potenti
candid
inhibit
replic
variou
virus
influenza
viru
iav
extrem
prone
caus
period
epidem
pandem
world
evolut
point
mutat
swap
gene
segment
correspondingli
present
vaccin
antivir
drug
principl
strategi
prevent
influenza
avail
antiinfluenza
drug
includ
inhibitor
neuraminidas
na
eg
oseltamivir
zanamivir
proton
channel
amantadin
rimantadin
rnadepend
rna
polymeras
rdrp
favipiravir
howev
influenza
vaccin
must
reformul
year
due
constant
antigen
evolut
influenza
addit
na
inhibitor
ionchannel
inhibitor
limit
efficaci
drug
resist
occurr
work
earli
phase
viru
infect
inher
properti
influenza
virus
mutat
result
low
efficaci
avail
drug
underscor
necess
develop
altern
strategi
provid
protect
pandem
influenza
widespread
util
directli
antivir
drug
acceler
resist
problem
henc
host
cellular
factor
becom
attract
therapeut
target
treat
influenza
viru
infect
recent
studi
pioneer
host
purin
metabol
pathway
conserv
process
respons
provid
host
cell
readi
suppli
guanosin
triphosph
gtp
critic
cellular
process
host
cell
could
produc
gtp
either
de
novo
pathway
salvag
pathway
de
novo
synthesi
gtp
impdh
catalyz
oxid
inosin
monophosph
imp
xanthosin
monophosph
xmp
ratelimit
step
grow
evid
support
inhibit
impdh
decreas
intracellular
level
guanosin
nucleotid
dna
rna
synthesi
therebi
indirectli
inhibit
viru
replic
requir
host
guanin
nucleotid
raw
materi
impdh
inhibitor
target
host
cell
would
less
suscept
select
drugresist
strain
earli
studi
establish
seri
novel
benzoheterocycl
amin
deriv
determin
vitro
antivir
activ
notabl
compound
show
potent
activ
toward
iav
low
micromolar
concentr
present
studi
develop
broadspectrum
antivir
activ
vitro
includ
oseltamivirresist
strain
amantadineresist
strain
influenza
viru
coxsacki
b
viru
coronaviru
respiratori
syncyti
viru
addit
examin
inhibitori
rate
compound
two
iav
envelop
glycoprotein
hemagglutinin
neuraminidas
investig
effect
express
enzym
activ
impdh
type
ii
result
indic
potenti
compound
antivir
activ
suppress
activ
impdh
type
ii
find
also
prove
develop
antiinfluenza
drug
direct
impdh
warrant
compound
n
methyl
fig
origin
provid
professor
zhuorong
li
institut
medicin
bioechnolog
chines
academi
medic
scienc
beij
china
pirodavir
biochempartn
oseltamivir
carboxyl
oc
medchem
amantadin
hydrochlorid
ah
sigmaaldrich
ribavirin
rbv
sigmaaldrich
use
refer
drug
vitro
pirodavir
ah
dissolv
dimethyl
sulfoxid
dmso
sigmaldrich
oc
rbv
dissolv
phosphat
buffer
salin
pb
gbico
cell
studi
purchas
america
type
cultur
collect
atcc
madindarbi
canin
kidney
mdck
cell
grown
minimum
essenti
medium
mem
invitrogen
contain
nonessenti
amino
acid
solut
neaa
invitrogen
penicillinstreptomycin
uml
invitrogen
fetal
bovin
serum
fb
gbico
african
green
monkey
kidney
vero
cell
human
lung
embryon
cell
cell
cultur
mem
supplement
antibiot
fb
respect
cell
grown
dmem
invitrogen
supplement
antibiot
fb
cell
cultur
presenc
co
influenza
viru
infect
mdck
cell
wash
pb
infect
influenza
viru
dilut
serumfre
medium
h
viral
inoculum
replac
mainten
medium
supplement
tpcktreat
trypsin
worthington
bsa
sigmaaldrich
viru
infect
viru
dilut
serumfre
medium
incub
cell
h
viral
inoculum
replac
mainten
medium
supplement
fb
cytotox
mdck
vero
evalu
cell
count
kit
cck
transgen
biotech
briefli
cell
seed
cultur
plate
mdck
cell
per
well
cell
per
well
vero
cell
per
well
h
later
cell
incub
serial
twofold
dilut
anoth
h
cck
ad
cell
absorb
read
nm
enspir
perkin
elmer
hour
incub
tc
defin
toxic
concentr
drug
determin
reed
muench
method
attach
cell
incub
viru
tcid
serumfre
medium
h
unconjug
virus
replac
mainten
medium
serial
twofold
dilut
posit
control
drug
reduct
virusinduc
cpe
record
cpe
viral
control
group
reach
accord
reed
muench
method
cellinhibitori
concentr
ic
select
index
si
calcul
ratio
tc
ic
compound
calcul
cell
collect
h
postinfect
lyse
mper
mammalian
protein
extract
reagent
contain
halt
proteas
inhibitor
cocktail
thermo
fisher
scientif
sampl
protein
subject
sdspage
transfer
pvdf
membran
millipor
block
milk
membran
incub
antibodi
influenza
santa
cruz
millipor
impdh
type
ii
sigmaaldrich
rsv
santa
cruz
coronaviru
santa
cruz
respect
hrpconjug
secondari
antibodi
incub
signal
detect
use
enhanc
chemiluminesc
ecl
kit
ge
healthcar
life
scienc
total
rna
extract
h
postinfect
purifi
use
rneasi
mini
kit
qiagen
onestep
quantit
realtim
rtpcr
carri
use
abi
fast
realtim
pcr
instrument
experi
perform
triplic
data
repres
mean
sd
p
versu
con
anova
appli
biosystem
use
superscript
iii
platinum
sybr
green
onestep
qrtpcr
kit
transgen
follow
condit
min
second
follow
cycl
mrna
iav
rsv
gapdh
amplifi
specif
primer
oligonucleotid
use
shown
tabl
sampl
normal
subtract
ct
valu
gapdh
rel
amount
viral
rna
calcul
inhibit
activ
assess
quantifi
fluoresc
product
enzymat
reaction
upon
cleavag
acid
munana
briefli
reaction
system
consist
sampl
enzym
substrat
buffer
mix
munana
mm
me
buffer
ph
mm
cacl
doubl
distil
water
substrat
buffer
mix
ad
incub
dilut
drug
sampl
enzym
min
room
temperatur
fluoresc
intens
read
incub
min
enspir
multimod
reader
perkinelm
excit
emiss
wavelength
nm
nm
respect
rel
fluoresc
obtain
subtract
background
valu
inhibitori
effect
compound
viral
attach
target
cell
assess
hi
assay
use
chicken
red
blood
cell
suspens
briefli
dilut
iav
mix
dilut
compound
u
bottom
plate
incub
min
equal
volum
chicken
erythrocyt
suspens
ad
well
erythrocyt
aggreg
evalu
visual
inspect
min
enzymat
assay
employ
evalu
inhibitori
effect
activ
impdh
type
ii
follow
increas
format
nicotinamideadenin
dinucleotid
nadh
absorb
read
nm
enspir
assay
buffer
contain
trishcl
ph
kcl
mm
edta
impdh
type
ii
sigmaaldrich
mm
dtt
nad
sigmaaldrich
reaction
start
addit
imp
final
concentr
mm
cytotox
effect
cell
viabil
includ
mdck
vero
cell
measur
cck
illustr
fig
accord
result
cytotox
select
non
toxic
dose
implement
subsequ
experi
antivir
activ
influenza
virus
obtain
method
cpe
mdck
cell
rbv
oc
ah
refer
drug
ic
si
valu
influenza
virus
shown
tabl
furthermor
display
fig
could
inhibit
aggreg
chicken
erythrocyt
caus
viral
hemagglutinin
bind
sialic
acid
receptor
cellular
membran
surfac
neg
control
drug
rbv
oc
also
show
inhibitori
effect
target
ha
result
suggest
probabl
target
two
iav
envelop
glycoprotein
requir
viru
adsorpt
releas
antivir
effect
like
attribut
inhibit
one
multipl
intracellular
replic
process
influenza
viru
ribavirin
demonstr
possess
broad
activ
sever
rna
dna
virus
includ
influenza
b
viru
measl
viru
parainfluenza
viru
impdh
demonstr
play
critic
role
viral
suppress
rbvmp
phosphoryl
form
rbv
accumul
evid
show
depress
impdh
inhibit
replic
divers
speci
virus
synthes
target
impdh
studi
effect
enzym
result
show
impdh
express
lessen
treatment
even
rbv
inhibit
either
hand
enzymat
reaction
rate
impdh
could
reduc
treatment
henc
antiinfluenza
activ
might
relat
inhibit
impdhdriven
enzymat
reaction
fig
extens
pharmacolog
activ
impdh
inhibitor
research
appli
clinic
consid
product
impdh
catalyz
reaction
necessari
viral
replic
also
exhibit
inhibitori
effect
virus
support
hypothesi
test
abil
protect
cell
infect
viru
cvb
rsv
coronaviru
exhibit
tabl
show
antivir
activ
differ
strain
refer
drug
pirodavir
cvb
refer
drug
rbv
addit
suppress
structur
protein
mrna
protein
express
dose
depend
manner
fig
next
evalu
inhibitori
action
rsv
coronaviru
replic
present
fig
markedli
decreas
rsv
mrna
protein
express
rsvinfect
cell
moreov
treatment
almost
complet
inhibit
express
viral
protein
addit
similar
suppress
toward
coronaviru
display
fig
taken
togeth
data
identifi
possess
broad
spectrum
antivir
activ
differ
strain
cvb
rsv
coronaviru
vitro
determin
vivo
toxic
preliminarili
femal
kun
ming
mice
gavag
mgkg
mgkg
twice
day
six
mice
enrol
group
gavag
vehicl
continu
administr
day
weight
day
respect
shown
tabl
bodi
weight
chang
mice
observ
group
found
signific
differ
group
vehicletr
control
group
ch
ch
oh
castor
oil
appli
parallel
solvent
control
indic
dose
mgkg
oral
administr
mice
littl
acut
toxic
long
time
infect
numer
differ
virus
brought
prodigi
threat
human
health
influenza
virus
display
consider
antigen
divers
new
strain
aris
antigen
mutat
alway
caus
pandem
world
therefor
key
challeng
search
novel
drug
target
broad
antivir
spectrum
difficult
gener
viral
resist
know
virus
alway
use
host
protein
signal
pathway
complet
replic
therefor
host
factor
attract
therapeut
target
treat
viru
infect
experi
perform
triplic
data
repres
mean
sd
p
p
p
versu
con
impdh
control
convers
imp
xmp
ratelimit
step
de
novo
synthesi
guanin
nucleotid
sinc
guanin
raw
materi
replic
viru
need
synthes
host
cell
inhibit
impdh
could
restrain
viru
replic
eventu
even
organ
tissu
produc
guanin
nucleotid
salvag
pathway
sever
phosphoribosyl
transferas
amount
guanin
nucleotid
meet
need
rapidli
grow
cell
virus
replic
influenza
viru
could
inhibit
downregul
guanin
nucleotid
synthesi
inhibit
activ
impdh
impdh
activ
determin
two
highli
conserv
isoform
type
type
ii
human
mammalian
cell
show
differ
biolog
function
compar
two
subtyp
impdh
worth
futur
studi
demonstr
antivir
effect
influenza
viru
includ
resist
strain
oseltamivir
amantadin
exclud
target
neuraminidas
hemagglutinin
found
antivir
mechan
may
involv
inhibit
guanin
nucleotid
synthesi
inhibit
activ
impdh
type
ii
impdh
necessari
viral
replic
antivir
effect
cvb
rsv
coronaviru
confirm
addit
show
littl
toxic
vivo
surviv
rate
bodi
weight
mice
detect
antivir
efficaci
vivo
base
result
believ
studi
impdh
inhibitor
prospect
futur
antivir
research
although
mani
impdh
inhibitor
develop
biolog
function
mechan
still
need
studi
addit
current
applic
impdh
inhibitor
side
effect
earli
studi
influenza
virusinfect
patient
rbv
administ
oral
elev
bilirubin
valu
may
reflect
destruct
rbvcontain
erythrocyt
lassa
fever
infect
patient
treat
oral
intraven
higher
dose
rbv
transient
anemia
also
observ
besid
side
effect
limit
use
mycophenol
mofetil
mmf
anoth
impdh
inhibitor
either
diarrhea
leucopenia
sepsi
vomit
advers
effect
fetal
research
occur
experiment
anim
highlight
urgent
need
reduc
toxic
impdh
inhibitor
therefor
perform
extens
laboratori
studi
pharmacokinet
pesticid
effect
toxic
vivo
provid
theoret
basi
druggabl
inhibit
replic
influenza
b
virus
includ
oseltamivir
amantadin
resist
strain
vitro
directli
target
two
envelop
glycoprotein
requir
viral
adsorpt
releas
instead
compound
could
depress
activ
impdh
type
ii
provid
strong
inhibit
replic
respiratori
syncyti
viru
coronaviru
enteroviru
divers
strain
coxsacki
b
viru
